Breaks Categories: News

WednesdayAug 02, 2023 1:26 pm

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Designing Human Clinical Study of DehydraTECH-CBD for Weight Loss, Diabetes Control

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today reported its intention to conduct a human clinical study to examine DehydraTECH-CBD for purposes of diabetes control and weight loss. Lexaria previously announced that, in its pre-clinical diabetes study DIAB-A22-1 in obese diabetic-conditioned animals, DehydraTECH-CBD achieved each of the following: lowered blood glucose levels by 19.9%; lowered overall body weight by 7% sustained over eight weeks; statistically significant increase in locomotor activity; lowered triglyceride levels by more than 25%; and lowered blood urea nitrogen levels by 27.9%. As a result of the very successful pre-clinical results, Lexaria…

Continue Reading

FridayJul 28, 2023 12:51 pm

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX, LEXXW) Announces New Subsidiary, Provides Update on Nicotine Study

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has incorporated a new wholly owned subsidiary: Lexaria Nutraceutical Corp., or LEXX Nutra. According to the announcement, LEXX Nutra was established to support Lexaria’s overall strategy of maximizing the potential for its patented DehydraTECH(TM) technology in a variety of markets. The company issued an exclusive perpetual license to LEXX Nutra, giving the new subsidiary rights to utilize, or sublicense the use of, DehydraTECH in an array of ways, including creating consumer packaged goods (“CPG”) and/or intermediate ingredients composed of any molecule except those associated with nicotine or cannabis. LEXX Nutra…

Continue Reading

FridayJul 21, 2023 11:30 am

CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Participation in Water Tower Research Fireside Chat Series

InMed Pharmaceuticals (NASDAQ: INM) is a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs. The company today announced that Jerry Griffin, VP of Sales and Marketing for InMed’s subsidiary BayMedica LLC, a leading supplier of bioidentical rare cannabinoids to the health and wellness (“H&W”) market, will be participating in a fireside chat with Water Tower Research on July 25, 2023, at 2:00 p.m. ET. The event is open for all investors with topics that include an overview of BayMedica, its competitive environment and upcoming catalysts, as well as the market dynamics of rare…

Continue Reading

ThursdayJul 20, 2023 12:04 pm

CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Issues Update on BayMedica Rare Cannabinoid Business

InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs, today provided a commercial and manufacturing update on its subsidiary BayMedica LLC, a leading supplier of bioidentical rare cannabinoids to the health and wellness (“H&W”) market. Among the highlights, the company reported a 123% quarter-over-quarter increase in revenues. “We are very encouraged to see another strong quarter with (unaudited) revenues in excess of $2.3M, representing our third consecutive quarter with significant revenue growth,” said Eric A. Adams, InMed’s president and CEO. “As demand for minor cannabinoids continues to increase, we…

Continue Reading

WednesdayJul 19, 2023 12:01 pm

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Expands Portfolio in Oral Nicotine Delivery Sector

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced that it was granted a strategically important new patent in the oral nicotine sector by the United States Patent and Trademark Office (“USPTO”). According to the update, U.S. patent #11,700,875 Compositions and Methods For Sublingual Delivery of Nicotine includes claims for many types of nicotine, including nicotine benzoate, nicotine ditartrate, nicotine citrate, nicotine polacrilex, and many others, for use in sublingual delivery formats like oral pouches. The company’s superior DehydraTECH processing and sublingual compositions have now been recognized through exceptional scientific study results as well as…

Continue Reading

ThursdayJun 22, 2023 11:48 am

CannabisNewsBreaks – InMed Pharmaceuticals Inc.’s (NASDAQ: INM) 755-201-EB Trial Demonstrates Clinically Important Results

InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs, today announced safety and efficacy results from its phase 2 clinical trial. The purpose of the trial, called “755-201-EB,” was to evaluate the safety of INM-755 CBN cream, which consists of the control cream plus the active pharmaceutical ingredient CBN, and obtain preliminary evidence of efficacy in treating symptoms and healing wounds over a 28-day period in patients with epidermolysis bullosa (“EB”). According to the announcement, of the 18 participants assessed, chronic itch improved by a clinically meaningful amount in…

Continue Reading

TuesdayJun 20, 2023 2:13 pm

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Expands IP Portfolio with Four New Patents

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced its receipt of four newly granted patents. The company secured two new Canadian patents, its 18th in its patent family No. 1: Food and Beverage Compositions Infused with Lipophilic Active Agents and Methods of Use Thereof, and No. 8 in its: Compositions Infused with Nicotine Compounds and Methods of Use Thereof. Lexaria was also granted two new U.S. patents under its patent family No. 21.  The first being for Pharmaceutical Compositions and Methods for Treating Hypertension, as well as the second being for Compositions and Methods…

Continue Reading

FridayJun 16, 2023 11:50 am

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports on Promising Results from Diabetes Animal Study

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, is releasing additional findings from its DIAB-A22-1 study, a diabetes animal study designed to evaluate the company’s proprietary DehydraTECH-CBD. DehydraTECH is a patented drug-delivery formulation and processing platform technology developed by Lexaria. The company noted that in addition to the three positive outcomes reported earlier — weight loss in obese diabetic-conditioned animals and improved triglyceride and cholesterol levels — the study has indicated a reduction in blood glucose levels and improvements in kidney function. These results were gathered after the company undertook a further round of analysis to explore additional study…

Continue Reading

MondayJun 12, 2023 1:13 pm

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Appoints Experienced Financial Professional as New CFO

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced the appointment of a new chief financial officer. Effective immediately, Mike Shankman will serve as outsourced CFO. An experienced accounting and finance professional, Shankman has held senior positions with companies in the biotechnology, medical devices and software-as-a-service industries. As a consultant with NOW CFO, one of his current clients is a publicly traded clinical-stage biopharmaceutical company. Former clients include a medical device maker for which Mike collaborated with independent auditors and investment bankers through the completion of an initial public offering. The client began trading on…

Continue Reading

ThursdayJun 01, 2023 11:41 am

CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Sponsored Research Presented at Canadian Neuroscience Meeting

InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids, today announced that results from a neurodegenerative disease study were presented in a scientific poster at the Canadian Neuroscience Meeting in Montreal from May 28-31, 2023. The InMed sponsored research demonstrated the ability of a specific rare cannabinoid (“pCBx”) in InMed’s 900 Series library of potential candidates that reduces amyloid toxicity and tau protein expression while enhancing neuronal cell growth and neuritogenesis markers in vitro. These are all considered to be important targets in the potential treatment of neurodegenerative diseases such as Alzheimer’s.…

Continue Reading